Pradaxa 150 mg/1 (Dabigatran Etexilate PELLET) 150 mg/1

Pradaxa 150 mg pellets are an oral medication used for blood thinning. This prescription drug helps manage certain cardiovascular conditions. Learn more about dabigatran etexilate uses and effects.

Strength

150 mg/1

Pack Size

1 BAG in 1 CARTON (0597-0450-16) / 60 PELLET in 1 BAG

Manufacturer / TM Owner

Boehringer Ingelheim Pharmaceuticals, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Pradaxa 150 mg pellets are primarily used to reduce the risk of blood clots and stroke in patients with atrial fibrillation. This medication is also used to treat deep vein thrombosis and pulmonary embolism. What is Pradaxa used for? It is often prescribed for conditions requiring anticoagulation therapy.

Side Effects

Common effects of Pradaxa may include bleeding, bruising, and gastrointestinal discomfort. Some users may experience dizziness or headache. It is important to monitor for signs of unusual bleeding while taking this medication.

Precautions & Warnings

Pradaxa should be handled with care, especially in patients with kidney problems or a history of bleeding disorders. Regular medical check-ups are recommended to monitor blood clotting levels. Always follow your healthcare provider's instructions for safe usage.

Avoid Interactions

Pradaxa may interact with other blood thinners, NSAIDs, and certain antibiotics. Alcohol consumption should be limited as it can increase the risk of bleeding. Always inform your healthcare provider about all medications you are taking.

Frequently Asked Questions

Pradaxa is used to prevent blood clots and reduce the risk of stroke in patients with atrial fibrillation. It is also used to treat deep vein thrombosis and pulmonary embolism.

Pradaxa pellets are taken orally, typically once or twice daily. They should be swallowed whole with water and can be taken with or without food.

Common side effects include bleeding, bruising, and gastrointestinal discomfort. Some users may also experience dizziness or headache.

Pradaxa may interact with other blood thinners, NSAIDs, and certain antibiotics. Always consult your healthcare provider before combining medications.

Pradaxa should be used with caution in patients with kidney problems. Regular monitoring and dosage adjustments may be necessary.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.